Table 1. Table showing the response rates and predominant toxicities for different PARP inhibitors in patients with advanced ovarian cancer.
|
BRCA1/2
mutant |
BRCA1/2
wild type and unknown |
|||||
|---|---|---|---|---|---|---|
| Drug | No. | Response | No. | Response | Predominant toxicity (in order of frequency) | References |
| Olaparib (AZD2281) | >100 (mostly platinum resistant) | 30–60% | 46 | Platinum sensitive 50% Platinum resistant 4% | GI symptoms, fatigue, anaemia | (Fong et al, 2010; Gelmon et al, 2011; Kaye et al, 2012) |
| Rucaparib (AG014699) | 39 (all platinum sensitive) | 69% | 132 | LOHhigh 29% LOHlow 13% | GI symptoms, fatigue, anaemia, transient ALT/AST elevations | (Kristeleit et al, 2015) |
| Niraparib (MK4827) | 20 (9 platinum sensitive) | 40% | 3 19 | Platinum sensitive 67% Platinum resistant 16% | Anaemia, thrombocytopenia, neutropenia, GI symptoms, fatigue | (Sandhu et al, 2013) |
| Talazoparib (BMN-673) | 26a | 46% | – | – | Fatigue, alopecia, GI symptoms, anaemia, neutropenia, thrombocytopenia | (Wainberg et al, 2014) |
| Veliparib (ABT-888) | 28a,b | 40% | 24a,b | 4% | Nausea, fatigue, lymphopenia | (Puhalla et al, 2014) |
Abbreviations: ALT=alanine transaminase; AST=aspartate transaminase; GI=gastrointestinal; LOH=loss of heterozygosity.
a
Platinum responsiveness not known.
b
Includes triple negative breast cancer.